M42 To Highlight Innovations In Laboratory Medicine And Genomics At ADLM Middle East Conference 2024

M42, a leader in global health technology, is advancing AI and genomics-driven medical solutions to transform healthcare in the UAE and beyond. At the ADLM Middle East Conference from 23rd to 24th November 2024, M42 will display its extensive diagnostic capabilities. This event, organised by the Association of Diagnostics & Laboratory Medicine (ADLM), will gather experts to discuss trends in diagnostic innovation.

The National Reference Laboratory (NRL) is crucial in UAE healthcare, conducting over 10 million tests yearly. It uses scientific expertise and AI to create solutions for complex disorders efficiently. With more than 5,000 tests across ten labs, NRL enhances laboratory service quality and efficiency, meeting clinical needs and reducing turnaround times.

Dr. Laila AbdelWareth, CEO of NRL, stated, "The National Reference Laboratory is committed to driving continuous medical education around laboratory medicine and bringing international best practices to the region. Our internationally accredited laboratories, operated by a world-class team of pathologists and clinical and biomedical scientists, bring specialised expertise across various disciplines of medicine."

M42's Omics Centre of Excellence manages the Emirati Genome Programme (EGP), which has sequenced over 600,000 Emirati genomes. This initiative shifts healthcare from a one-size-fits-all model to precise prevention-based care. The EGP sets a global standard for population genomics with initiatives like premarital screening and pharmacogenomics.

Dr. Val Zvereff, Medical Director at M42’s Omics Centre of Excellence, explained that programs like premarital screening use genetic data to identify hereditary risks early. "Through operating the Emirati Genome Programme (EGP), M42 is revolutionizing healthcare in the UAE with population-scale genomic initiatives that enable preventive, precise and predictive care," he said.

Impact on Healthcare Delivery

The EGP's comprehensive genetic data allows early identification of genetic risks, empowering patients with actionable insights. This often shortens diagnostic journeys and reduces financial burdens. Whole genome sequencing increases diagnostic accuracy for rare diseases by 31% compared to standard tests.

M42’s efforts are reshaping healthcare delivery by moving beyond data collection to practical applications that empower clinicians with actionable insights. By advancing accurate diagnoses and tailored treatments, the EGP redefines care standards and contributes to a healthier future for the UAE.

M42 continues its mission to enhance health outcomes through innovative solutions in diagnostics and genomics. Its participation in events like the ADLM Middle East Conference underscores its commitment to improving healthcare infrastructure in the UAE while setting benchmarks globally.

With inputs from WAM